107 related articles for article (PubMed ID: 26793881)
21. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
22. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
[TBL] [Abstract][Full Text] [Related]
23. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
24. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
[TBL] [Abstract][Full Text] [Related]
25. Androgen Signaling in Prostate Cancer.
Dai C; Heemers H; Sharifi N
Cold Spring Harb Perspect Med; 2017 Sep; 7(9):. PubMed ID: 28389515
[TBL] [Abstract][Full Text] [Related]
26. Uncovering the roles of miRNAs and their relationship with androgen receptor in prostate cancer.
ChunJiao S; Huan C; ChaoYang X; GuoMei R
IUBMB Life; 2014 Jun; 66(6):379-86. PubMed ID: 24979663
[TBL] [Abstract][Full Text] [Related]
27. The emerging role of noncoding RNA in prostate cancer progression and its implication on diagnosis and treatment.
Takayama K; Inoue S
Brief Funct Genomics; 2016 May; 15(3):257-65. PubMed ID: 26685282
[TBL] [Abstract][Full Text] [Related]
28. The mutational landscape of lethal castration-resistant prostate cancer.
Grasso CS; Wu YM; Robinson DR; Cao X; Dhanasekaran SM; Khan AP; Quist MJ; Jing X; Lonigro RJ; Brenner JC; Asangani IA; Ateeq B; Chun SY; Siddiqui J; Sam L; Anstett M; Mehra R; Prensner JR; Palanisamy N; Ryslik GA; Vandin F; Raphael BJ; Kunju LP; Rhodes DR; Pienta KJ; Chinnaiyan AM; Tomlins SA
Nature; 2012 Jul; 487(7406):239-43. PubMed ID: 22722839
[TBL] [Abstract][Full Text] [Related]
29. Identification of long non-coding RNAs in advanced prostate cancer associated with androgen receptor splicing factors.
Takayama KI; Fujimura T; Suzuki Y; Inoue S
Commun Biol; 2020 Jul; 3(1):393. PubMed ID: 32704143
[TBL] [Abstract][Full Text] [Related]
30. Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma.
Laudato S; Aparicio A; Giancotti FG
Trends Cancer; 2019 Jul; 5(7):440-455. PubMed ID: 31311658
[TBL] [Abstract][Full Text] [Related]
31. Horizon scanning for novel therapeutics for the treatment of prostate cancer.
Bianchini D; Zivi A; Sandhu S; de Bono JS
Ann Oncol; 2010 Oct; 21 Suppl 7():vii43-55. PubMed ID: 20943642
[TBL] [Abstract][Full Text] [Related]
32. Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment.
Grubisha MJ; DeFranco DB
Steroids; 2013 Jun; 78(6):538-41. PubMed ID: 23380371
[TBL] [Abstract][Full Text] [Related]
33. [Disorder of signal transduction concerning carcinogenesis and progression without androgen receptor interaction in prostate cancer].
Matsumoto H; Matsuyama H
Nihon Rinsho; 2016 May; 74 Suppl 3():116-21. PubMed ID: 27344714
[No Abstract] [Full Text] [Related]
34. Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting.
Pienta KJ; Walia G; Simons JW; Soule HR
Prostate; 2014 Feb; 74(3):314-20. PubMed ID: 24249419
[TBL] [Abstract][Full Text] [Related]
35. A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer.
McAllister MJ; Underwood MA; Leung HY; Edwards J
Transl Res; 2019 Apr; 206():91-106. PubMed ID: 30528321
[TBL] [Abstract][Full Text] [Related]
36. [Mechanism of development and progression in prostate cancer: Overview].
Teishima J; Matsubara A
Nihon Rinsho; 2016 May; 74 Suppl 3():80-6. PubMed ID: 27344708
[No Abstract] [Full Text] [Related]
37. Signaling lansdscape of prostate cancer.
Lin X; Aslam A; Attar R; Yaylim I; Qureshi MZ; Hasnain S; Qadir MI; Farooqi AA
Cell Mol Biol (Noisy-le-grand); 2016 Jan; 62(1):45-50. PubMed ID: 26828986
[TBL] [Abstract][Full Text] [Related]
38. Molecular heterogeneity in prostate cancer and the role of targeted therapy.
Khan S; Baligar P; Tandon C; Nayyar J; Tandon S
Life Sci; 2024 Jan; 336():122270. PubMed ID: 37979833
[TBL] [Abstract][Full Text] [Related]
39. [Recent trend in the development of novel treatments based on the mechanisms of prostate cancer progression].
Inoue T; Narita S; Habuchi T
Nihon Rinsho; 2016 May; 74 Suppl 3():211-20. PubMed ID: 27344731
[No Abstract] [Full Text] [Related]
40. Androgen receptor functions in prostate cancer development and progression.
Balk SP
Asian J Androl; 2014; 16(4):561-4. PubMed ID: 24759584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
